Antibody reduction therapy for worsening pulmonary fibrosis
Treatments studied
Part of Lungs & breathing clinical trials.
This trial tests a treatment that reduces certain antibodies in your blood, which may help slow the progression of IPF. The treatment involves a procedure to filter your blood and then giving you antibodies to help your immune system.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 40 and 85 years old.
- You need a confirmed diagnosis of Idiopathic Pulmonary Fibrosis (IPF) that is getting worse.
- Your lung function (FVC) must have dropped by more than 10% in the past year.
- You must have received a recent COVID-19 vaccine (within 1 to 26 weeks before starting).
- You cannot have certain infections like hepatitis B or C, or uncontrolled health conditions like diabetes or high blood pressure.
- You must be willing to receive blood product transfusions and follow all study requirements.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a new antibody drug, ABBV-142, to see if it can reduce disease activity in adults with idiopathic pulmonary fibrosis (IPF). It may help if your IPF was diagnosed within the last 7 years and you meet certain health criteria.
This trial tests whether giving a medication called intravenous immunoglobulin (IVIG) can help people with IPF who are hospitalized for a sudden worsening of their lung condition. The treatment aims to reduce inflammation and improve recovery.
This trial tests an experimental pill called rentosertib for people with idiopathic pulmonary fibrosis (IPF), a lung disease that causes scarring. The study aims to see if the drug can slow down the disease and improve breathing.
This study uses detailed CT scans to find better ways to treat idiopathic pulmonary fibrosis (IPF). It may help doctors choose the right treatment for each person.
This study tests an experimental pill called SYH2059 for people with IPF, a condition that causes lung scarring and makes breathing harder. The goal is to see if the pill is safe and can help slow down the disease.
This trial tests an oral medication, ifetroban, to see if it can slow the progression of idiopathic pulmonary fibrosis (IPF), a lung condition that causes scarring. It aims to improve breathing and lung function in patients with IPF.
Hear when a new Idiopathic Pulmonary Fibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.